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Objective.T oe v a l u a t el o n g - t e r me ﬀectiveness and safety of conservative and minimally invasive outpatient treatments for female
stress urinary incontinence (SUI) through a review of the literature. Methods. PubMed was searched for reports on prospective
clinicaltrialswithatleast12-monthfollow-upofminimallyinvasivetreatments,pelvicﬂoorrehabilitation,orpharmacotherapyin
women with SUI. Each report was examined for long-term rates of eﬀectiveness and safety. Results. Thirty-two clinical trial reports
were included. Prospective long-term studies of pelvic ﬂoor rehabilitation were limited but indicated signiﬁcant improvements
with treatment adherence for at least 12 months. Poor initial tolerability with duloxetine resulted in substantial discontinuation.
Most patients receiving transurethral radiofrequency collagen denaturation or urethral bulking agents reported signiﬁcant long-
term improvements, generally good tolerability, and safety. Conclusions. Conservative therapy is an appropriate initial approach
for female SUI, but if therapy fails, radiofrequency collagen denaturation or bulking agents may be an attractive intermediate
management step or alternative to surgery.
1.Introduction
Female patients with stress urinary incontinence (SUI)
typically present with a complaint of involuntary urine
leakageuponcoughingorsneezing,exertion,orwithchanges
in posture [1, 2]. This condition is caused by weakening
of the pelvic ﬂoor muscles that support the bladder and
urethra (e.g., urethral hypermobility) and/or by weakness
of the urethral sphincter (i.e., intrinsic sphincter deﬁciency
[ISD]) [3]. Prevalence estimates vary widely, ranging from
4% to 35% of women [2, 4] .A g i n g ,o b e s i t y ,w h i t er a c e ,p r e g -
nancy and vaginal childbirth, vaginal or pelvic surgery, and
smokingarewell-establishedriskfactorsforthedevelopment
of SUI [3, 5]. Although many women do not immediately
seek treatment for SUI symptoms [3, 6], the negative impact
of SUI on daily functioning, sexual relationships, and overall
quality of life [4, 7] are factors that can eventually prompt
women to discuss treatment options with their health care
providers.
Widely used for ﬁrst-line treatment, pelvic ﬂoor reha-
bilitation primarily comprises pelvic ﬂoor muscle training
(PFMT), also known as Kegel exercises, and may include
pelvic muscle electrical stimulation, biofeedback, or the
u s eo fp h y s i c a ld e v i c e s ,s u c ha sv a g i n a lc o n e so rp e s s a r i e s
[8–10]. Typically when a conservative therapy fails, phar-
macotherapy may be considered as a next management
step. However, while the selective norepinephrine reuptake
inhibitor duloxetine is approved for treatment of SUI in
many countries, no pharmacologic treatments are approved
in the US [5, 9]. Historically, when pelvic ﬂoor rehabilitation
fails, surgical intervention remains a popular treatment
option for women with moderate to severe SUI. Retropubic
suspensionandslingproceduresareassociatedwith6-month
short-term cure rates as high as 85% to 90% [3], with
one long-term retrospective study reporting a cure rate
plateau of about 69% at 10 to 12 years postsurgery [11].
While less invasive surgical options known as minislings
were recently approved, they appear to be less eﬀective than2 Advances in Urology
traditionalslings[12–14]andposetheriskofrarebutserious
complications, most frequently erosion through the vaginal
epithelium [3, 15, 16].
Surgery of any type, however, is not suitable for all
patients. In particular, women with signiﬁcant comorbidities
may not be good surgical candidates. Moreover, some
otherwise healthy SUI patients may ﬁnd unacceptable the
associated risks, pain, and recovery time, with no exertional
activities, lifting more than 5 to 10 pounds, and sexual
activity for 6 weeks, and choose to forgo surgery, despite
continuing SUI symptoms.
As an alternative to surgery, minimally invasive nonsur-
g i c a lp r o c e d u r e sf o rt h em a n a g e m e n to fS U Ih a v eb e c o m e
available. These include transurethral radiofrequency colla-
gen denaturation, which is indicated only for patients with
SUI due to urethral hypermobility, and the injection of
bulking agents, which is indicated only for patients with
SUI due to ISD. Results from shorter-term, randomized
clinical trials have demonstrated eﬃcacy with these therapies
(versus no treatment or baseline) [17, 18]. Both types of
procedure appear to be generally well tolerated [17, 19]
in the respective patient populations, and neither appears
to limit the possibility of later surgery. In light of their
growing use, it is necessary to determine how each of these
options compares with established conservative approaches
with regard to long-term durability of beneﬁt.
This paper aims to evaluate available evidence concern-
ing long-term (12 months or longer) eﬃcacy of minimally
invasive treatments forfemale SUI. To establish a baseline for
comparison, long-term results with pelvic ﬂoor rehabilita-
tion and pharmacotherapy were also included. The literature
was searched to identify prospective clinical trials conducted
in women with SUI with a minimum study duration of 12
months.
2. Methods
2.1. Literature Search Strategies. PubMed searches were
conducted in January 2010 and were limited to papers
on clinical or randomized controlled trials conducted in
humans and published in the English language. Patient
populations were limited to adult females. No restrictions
with regard to the country of publication were applied to any
search,norwerepublicationdateslimitedtoanyspeciﬁctime
periods.Theprimarytermsusedinallsearcheswere“urinary
incontinence OR urinary stress incontinence OR urinary
incontinence, stress.” These terms were combined with
speciﬁcadditionaltermsinbooleansearchestolocatearticles
on conservative therapies, pharmacotherapy, transurethral
radiofrequency collagen denaturation, and bulking agents
used for treatment of SUI.
To identify articles on studies of pelvic ﬂoor rehabilita-
tion, secondary terms used in the boolean search included
“physiotherapyORpelvicﬂoormuscletrainingORKegelOR
muscle OR electrical stimulation OR pessaries OR pessary
OR biofeedback OR biostimulation OR cone OR vaginal
cone OR physical therapy modalities OR rehabilitation.” The
only secondary term used to search for articles on pharma-
cotherapy was “duloxetine,” as that is the only medication
formally approved in some countries for treatment of SUI.
For identifying publications on transurethral radiofrequency
collagen denaturation, the secondary terms “Renessa OR
radiofrequency OR radiofrequency collagen denaturation
OR radiofrequency micro-remodeling OR electromagnetic
ﬁelds” were used. Searches to identify trials of bulking agents
were limited to products approved by the Food and Drug
AdministrationfortreatmentofSUI.Secondarysearchterms
were “injection OR collagen OR biocompatible materials OR
bulking agents OR Contigen OR Durasphere OR Uryx OR
Coaptite OR Macroplastique.”
2.1.1. Supplemental Searches. An additional search of
PubMed to identify potential articles was conducted using
thesecondaryterms“systematicreviewORmeta-analysis.”A
search of the Cochrane Library was also conducted. The full-
text versions of all relevant articles were obtained, and the
bibliographiesweremanuallyreviewedforadditionaleligible
study reports.
2.2. Eligibility Criteria and Study Selection. The eligibility of
each study was assessed based on search results. Studies were
eligible for inclusion if they were prospectively designed,
all patients were females aged 18 years or older, and the
study duration was at least 12 months after initiation of
treatment. To gain a historical perspective of the long-term
eﬀectiveness of pelvic ﬂoor rehabilitation, this search was
originally limited to studies describing a comparison of
therapies or comparison of a therapy versus placebo or no
treatment,andemployingarandomizedorquasirandomized
(i.e.,allocationbyalternation)design.Relevantstudydesigns
were required to deﬁne PFMT as a regimen wherein
the proper procedure for performing pelvic ﬂoor muscle
contractions was taught by a health care professional, and
theexerciseswereperformedbypatients inrepeatedsetsona
regular basis. Following the original searches, however, it was
discovered that few randomized, controlled, blinded trials
of at least 12 months in duration existed in the literature,
and the criteria for inclusion were adjusted to permit the
assessment of the best available evidence for each treatment.
Exclusion criteria included articles reporting on case
reviews, studies of urinary incontinence related to signiﬁcant
factors outside the urinary tract (e.g., neurologic disor-
ders, cognitive impairment, lack of independent mobility),
nocturnal enuresis, studies that recruited men (e.g., SUI
following prostatectomy), studies that included antenatal or
postnatal women (within 3 months of delivery), bladder
training studies, and studies that included patients with urge
incontinence and did not distinguish between subgroups
adequately to identify SUI data. Additionally, studies of
therapies that are no longer marketed or that are not
approved for treatment of SUI were excluded.
3. Results
The primary literature search yielded 729 potential publica-
tions. Additionally, 6 articles revealed during manual scans
of the bibliographies of 14 systematic reviews found during
supplemental searches of PubMed [5, 9, 20–23] and theAdvances in Urology 3
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Figure 1: Search results and article selection.
Cochrane Library [24–31] were considered to be potentially
eligible. In total, 31 studies involving 7038 patients with
SUI met the inclusion criteria. Figure 1 illustrates the
details of each search process. Eligible publications included
3 articles on pelvic ﬂoor rehabilitation, 2 on duloxetine
pharmacotherapy, 6 on transurethral collagen denaturation,
and 20 on bulking agent treatments. Eﬃcacy outcomes most
commonly used in these trials were “cured,” deﬁned as
complete absence of incontinence episodes, and “improved,”
deﬁned as a reduction from baseline in incontinence grade
or severity. Several studies also used the terms “continent” or
“dry,” with deﬁnitions varying between no further SUI leaks
and leakage less than a prespeciﬁed amount. Other outcome
measures often included the number of incontinence pads
used per day and the frequency of SUI episodes.
3.1. Long-Term Results from Pelvic Floor Rehabilitation. As
summarized in Table 1, the literature search identiﬁed three
long-term prospective trials of pelvic ﬂoor rehabilitation
involving 694 patients, with mean ages ranging from 31
to 69 years [32–34]. In these trials, PFMT regimens varied
widely. All three trials had a 12-month end point, and
patients were randomized to treatment groups. In one trial,
all patients performed 20 pelvic ﬂoor muscle contractions
5 times daily. One group performed PFMT alone, while
three groups received either PFMT therapy with reminders
(stickers), PFMT with reminders and patient education, or
PFMT with reminders, patient education, and counseling
by a physiotherapist [32]. In another trial, after 12 weeks
of training with a physiotherapist, patients completed 20-
minute at-home sessions of PFMT with biofeedback 5 days
per week. One group used a personal biofeedback monitor
device [33]. In the ﬁnal study, at-home Kegel exercises
were performed 5 times daily, eventually decreasing to
twice daily, with patients also receiving either eleven 30-
minute individual or nine 2-hour group sessions with a
physiotherapist [34].
In all three studies, SUI symptoms showed signiﬁcant
improvement at 3 months that was maintained at ﬁnal
follow-up in most patients. Improvement was shown in
patient-reported SUI symptoms in two of the studies [32,
34] and, in the other, in electromyographically (EMG)
assessed muscle electrical activity [33]. In all three trials,
PFMT eﬃcacy was comparable, regardless of whether it
w a sp e r f o r m e da l o n ev e r s u si nag r o u p[ 34], with patient
education [32], or paired with at-home biofeedback [33].
The positive outcomes reported in one trial [33], however,
are diﬃcult to interpret because ﬁndings were reported
separately for patients who failed therapy versus those with
treatment success. In the trial conducted by Aukee et al.,
14 of 35 patients (40%) had undergone or were scheduled
for incontinence surgery during long-term follow-up, while
patients without surgery who adhered to therapy continued
to show positive outcomes (Table 1).
Safety and tolerability were not described in these
reports. In the trial by Aukee et al. [33], the EMG-
assisted biofeedback device was described as “not harmful”
by patients, and no adverse events with device use were
reported.
3.2. Pharmacotherapy. The search yielded no randomized
controlled trials of duloxetine (Yentreve, AriClaim; Eli Lilly,4 Advances in Urology
Table 1: Summary of conservative therapy trials.
Study N Age, y Treatment Study design Study
duration Eﬃcacy measures Eﬃcacy outcomes
Alewijnse et al.
2003 [32]
129 Mean,
55.6
PFMT alone (control;
n = 32)
PFMT + reminders (n = 29)
PFMT + reminder + patient
education guide (n = 34)
PFMT + reminder + patient
education guide +
counseling (n = 34)
Randomized,
controlled,
open label
12mos Self-administered
questionnaires; diaries
Overall 75% cured or
improved at 12 mos
Overall reduction in
number of SUI episodes
in all groups from mean
23/wk to 8/wk; P<. 001
Eﬃcacy between all
treatment groups,
P = NS
Aukee et al.
2004 [33]
35
Mean,
49.4,
51.4
Range,
31–69
PFMT alone (control;
n = 19)
PFMT+ biofeedback, with
at-home EMG training
device (n = 16)
Randomized,
controlled,
open label
12mos
EMG-evaluated pelvic
ﬂoor muscle activity;
need for surgical
intervention after
conservative treatment;
patient assessment using
leakage index (based on
13 types of physical
exertion that may trigger
SUI episodes)
Nonoperated EMG
results:
PFMT, P = .02
PFMT+ biofeedback,
P = .005
Treatment failure
(surgery), n = 14
Only nonoperated
biofeedback group
achieved signiﬁcant
reduction in leakage
index, P = .005
Janssen et al.
2001 [34]
530 Mean,
47.8
PFMT, group sessions
(n = 404)
PFMT, individual sessions
(n = 126)
Randomized,
open label 12
Written questionnaires;
diaries; patient exercise
forms
Reduction in number of
SUI episodes versus
baseline:
Group, P<. 001
Individual, P<. 001
Group versus individual,
P = NS
Abbreviations: EMG, electromyography; NS, not signiﬁcant; PFMT, pelvic ﬂoor muscle training; SUI, stress urinary incontinence.
Indianapolis,IN)withastudydurationofatleast12months.
The search did reveal results from two long-term, open-label
trials of duloxetine therapy for SUI, which are described
in Table 2 [35, 36]. These trials assessed a total of 4167
patients who took duloxetine at the recommended dosage of
40mg bid for up to 30 months. Across these trials, patient
discontinuation rates ranged from 57.5% to 91%. In the trial
by Vella et al., most women discontinued duloxetine therapy
within 4 weeks of initiation, citing side eﬀects (45.2%) or
perceived lack of eﬃcacy (23.7%) as the primary reason
for discontinuation [35]. In the study by Bump et al. [36],
57.4% to 71.5% of women who continued with long-term
duloxetine therapy at end point reported that their SUI
symptoms were “much” or “very much” improved. In line
withthis, a subsetof these womenthroughout follow-upand
at end point reported an approximate 60% to 70% reduction
in the frequency of incontinence episodes. These reports
described neither the nature of common adverse events
with duloxetine nor adverse events leading to treatment
discontinuation.
3.3. Transurethral Radiofrequency Collagen Denaturation
Studies. Althoughbulkingagentsandtransurethralradiofre-
quency collagen denaturation (Renessa; Novasys Medical,
Inc., Newark, CA) are both nonsurgical treatment options
for women with SUI, they are indicated for use in diﬀerent
patient populations. The one-time radiofrequency collagen
denaturation procedure requires no incisions and can be
performed with the use of local anesthesia in a physician’s
oﬃce or outpatient treatment center. The procedure utilizes
a probe shaft with a balloon tip to deliver low levels of
radiofrequency energy at 65◦C, creating localized micro-
scopic collagen denaturation sites within the bladder neck
and proximal urethra without creating strictures, ﬁbrosis,
signiﬁcant tissue necrosis, gross shrinkage, or neurovascular
injury. The denatured collagen results in reduced dynamic
compliance of the surrounding untreated tissue [17, 37].
Following the procedure, the patient typically voids and
leaves the treatment site within an hour.
As summarized in Table 3, ﬁve trials of transurethral
radiofrequency collagen denaturation (N = 371) [37–41]
were identiﬁed by the original literature search. An addi-
tionalsearchpriortopublicationforarticlesdetailingfollow-
up results from an ongoing study revealed one new article
[42]. The longest follow-up period described was 3 years
[40].Anearly12-monthstudybySotomayorandBernal[37]
examined the use of four diﬀerent timing and placement
methods for the delivery of radiofrequency energy (e.g.,
60-second versus 90-second increments). Cure rates ranged
from22%to67%,withreductionsinepisodefrequencyfrom
67% to 89% of patients. In a later randomized, controlled
trial[41],leakpointpressurewassigniﬁcantlyimprovedwithAdvances in Urology 5
Table 2: Summary of pharmacotherapy trials.
Study N Age, y Treatment Study design Study
duration Eﬃcacy measures Eﬃcacy outcomes
Bump et al.
2008 [36]
Cohort A:
1424
Cohort B:
2515
Cohort A:
53.2
Cohort B:
55.5
Duloxetine
40mg bid
Pooled analysis
Cohort A: 3
randomized,
placebo-controlled,
double-blind studies
and 1 open-label,
single arm trial
Cohort B: one
randomized,
placebo-controlled,
double-blind study
30mos
18mos
Cohort A: PGI-I
scores;
discontinuation
rates
Cohort B: PGI-I
scores; diaries;
discontinuation
rates
PGI-I much or very much better:
Cohort A: 71.5%
Cohort B: 57.4%
Decrease in SUI episodes at end
point:
Cohort A: N/A
Cohort B: ≈70%
Discontinued by 12 months:
Cohort A: 57.5%
Cohort B: 79.5%
Vella et al.
2008 [35] 228 N/A Duloxetine
40mg bid
Open label, single
arm 12mos Discontinuation
rates
Discontinued by 4 wks: 69%
Discontinued by 12 mos: 91%
At 12 mos, 10 women were on no
treatment and had not
undergone surgery; of these, 6
were considered cured
Abbreviations: N/A, not available; PGI-I, Patient Global Impression-Improvement rating scale.
radiofrequency collagen denaturation versus an identically
performed sham treatment at 12 months posttreatment.
Furthermore, patients with moderate to severe SUI demon-
strated a signiﬁcant improvement in quality of life compared
with the sham treatment arm (P = .04). One retrospective
analysis of this trial found that outcomes did not diﬀer based
on menopausal status and use of hormonal replacement
therapy [38]. The long-term durability of this treatment was
reported in a 3-year follow-up study by Appell et al. that
found that 56% of women who underwent radiofrequency
collagen denaturation continued to report a 50% or greater
reduction in SUI episode frequency [40].
In a report by Elser et al., 12-month results from an
ongoing 36-month study showed that 45% of patients were
considered dry, with 29% experiencing no leaks and 16%
leaking less than 1 gram on a standardized in-oﬃce pad
weight test. Additionally, 69% of women experienced a
50% or greater reduction in leakage, and 71% reported
improvements on quality of life measures. A follow-up
report from the same study revealed that 61.7% of evaluated
patients continued to experience at least a 50% reduction
in SUI leaks at 18 months [42]. These studies showed
radiofrequency collagen denaturation to be generally safe
and well tolerated. Overall, adverse events were transient and
mild, including dysuria, urgency, and urinary tract infection,
with no serious adverse events reported.
3.4. Bulking Agents. W o m e nw i t hS U Id u et oI S Dm a ye l e c t
to undergo nonsurgical treatment with a bulking agent. As
with transurethral collagen denaturation, these treatments
may be administered in a physician’s oﬃce or outpatient
treatment center with the use of local anesthesia. The agents
are injected through a needle placed transurethrally through
a urethroscope or periurethrally lateral to the urethra while
observing the proximal urethra through a urethroscope;
they work by augmenting the urethral sphincter. Typically,
patients may leave the treatment site about 1 hour following
treatment.
The literature search revealed 20 trials meeting the
inclusion criteria that evaluated ﬁve types of bulking agents
(Table 4). Among them, nine investigations (N = 682) [19,
43–50] described the long-term eﬃcacy of glutaraldehyde
cross-linked (GAX) collagen (Contigen; Bard, Covington,
GA). Patients typically received an initial series of 1 to
4 transurethral injections over several months, as needed.
Rates of patients deemed cured or improved ranged from
21% to 81% at 12 months, 7% to 52% at 2 years, and 30%
to 43% at more than 4 years. Notably, however, the studies
with end points of more than 4 years reported that patients
required repeated collagen injections during the follow-up
period to restore improvement [19, 46]. Similarly, two long-
term trials [51, 52]( N = 321) of carbon-coated zirconium
beads (Durasphere; Carbon Medical Technologies, St. Paul,
MN) reported cure or improvement rates between 35% and
80% at 1 year, but eﬃcacy at 3 years [51] declined, with
only 21% of patients reporting improvement. Adverse events
withtheseagentsincludedurinaryurgency,transienturinary
retention, diﬃculty voiding, and urinary tract infection.
Among eight long-term trials (N = 507) [54–61]
of cross-linked polydimethylsiloxane injections (Macroplas-
tique; Uroplasty, Minnetonka, MN), cure rates at 12 months
posttreatment ranged between 20% and 71%, with improve-
ment rates between 19% and 48% (Table 4). With follow-up
extending up to 60 months, cure rates ranged from 18% to
40% and improvement rates ranged between 33% and 39%,
with repeated injections required to maintain eﬃcacy [59,
61]. A study of the injectable agent calcium hydroxylapatite
(Coaptite; Boston Scientiﬁc, Natick, MA; N = 296) [62]
showed similar long-term results. Reported adverse events
included transient urinary retention, urgency, dysuria, and
urinary tract infections.6 Advances in Urology
Table 3: Summary of transurethral radiofrequency collagen denaturation trials.
Study N Age, y Treatment Study design Study
duration
Eﬃcacy
measures Eﬃcacy outcomes
Appell et al.
2006 [41] 173
Mean, 50
Range,
22–76
One-time
radiofrequency
collagen
denaturation
(n = 110)
Sham procedure
(n = 63)
Randomized,
sham-controlled,
single blind
12mos I-QOL scores;
LPP testing
≥10-point I-QOL
improvement:
Treated patients: 48%
Sham: 44%
Mean LPP:
Treated patients: 13.2 ±
39.2cmH2O increase versus
Sham patients: −2.0 ±
33.8cmH2O; P = .02
Appell et al.
2007 [40] 21
Mean,
52.2
Range,
39.0–65.4
One-time
radiofrequency
collagen
denaturation
Retrospective
follow-up of a
12-month trial
36mos Diaries; I-QOL
scores
Mean I-QOL scores improved
12.7 points
≥50% decrease in SUI
episodes: 56%
Elser et al.
2009 [39] 136
Mean, 47
Range,
26–87
One-time
radiofrequency
collagen
denaturation
Open label, single
arm, interim
results
12mos
Diaries;
in-oﬃce stress
pad weight
tests; I-QOL
scores; UDI-6
scores; PGI-I
scores
≥50% decrease in SUI
episodes: 50%
≥50% reduction in leakage:
69%; 45% of patients were dry
Mean I-QOL scores improved
9.5 points
Mean UDI-6 scores improved
14.1 points
PGI-I “a little,” “much,” or
“very much” better: 50%
Elser et al.
2010 [42] 136a
Mean, 47
Range,
26–87
One-time
radiofrequency
collagen
denaturation
Open label, single
arm, interim
results
18mos
Diaries; I-QOL
scores; UDI-6
scores; PGI-I
scores
≥50% decrease in SUI
episodes: 47%
Mean I-QOL scores improved
10.9 points
Mean UDI-6 scores improved
13.0 points
PGI-I “a little,” “much,” or
“very much” better: 47%
Lenihan et al.
2005 [38]
73b women
in a subgroup
with baseline
moderate to
severe SUI
N/A
One-time
radiofrequency
collagen
denaturation
(n = 43)
Sham procedure
(n = 30)
Post hoc analysis
of a randomized,
sham-controlled,
single-blind study
12mos I-QOL scores
≥10-point I-QOL
improvement:
Treated patients: 74%
Sham: 50%
P = .03
Sotomayor and
Bernal 2005
[37]
41
Mean,
47.6
Range,
34–81
One-time
radiofrequency
collagen
denaturation,
with varying
submucosal
targets (4
subgroups)
Quasirandomized 12mos
I-QOL scores;
physician-
administered
questionnaire
Mean I-QOL scores improved
16–24 points
≥50% decrease in SUI
episodes: 63%–89%
Cured: 22%–67%
Abbreviations: I-QOL, Incontinence Quality of Life questionnaire; LPP, leak point pressure; PGI-I, Patient Global Impression of Improvement; SUI,s t r e s s
urinary incontinence; UDI-6, Urogenital Distress Inventory.
aThese patients were already counted in Elser et al. 2009 [39], thus they were not included in the total patient numbers as given in the text.
bThese patients were already counted in Appell et al. 2006 [41], thus they were not included in the total patient numbers as given in the text.
4. Discussion
While randomized controlled trials are generally considered
to be the best evidence, it appears that it may be diﬃcult
to conduct such trials in women with SUI, most likely
because each treatment involves diﬀerent methods, making
blinding diﬃcult. Also, treatments such as transurethral
radiofrequency collagen denaturation and bulking agents
are indicated for use in diﬀerent patient populations, mak-
ing head-to-head comparisons implausible. Thus the bestAdvances in Urology 7
Table 4: Summary of included bulking agent trials.
Study N Age, y Treatment Study design Study
duration Eﬃcacy measures Eﬃcacy outcomes
Glutaraldehyde cross-linked (GAX) collagen
Bent et al. 2001
[50]
90
Mean, 60.9
Range,
35–86
Up to 3 injections, as
needed, over 6 mos
Open label,
single arm 12mos
Continence grade;
diaries; LPP
testing, QOL
questionnaire
Dry: 21%
Improved: 21%
Improved LPP: 54%
QOL improvement: 62%
≥1 continence grade
improvement: 21%
Corcos and
Fournier
1999 [19]
40
Mean, 2.3
Range,
38–82
Up to 5 injections,
as needed
Open label,
single arm
Mean
follow-up,
50mos
Direct patient
questioning; PVR
test; stress pad
weight test;
Valsalva LPP
Cured: 30%
Improved: 40%
All cured patients had PVR
<10mL and negative pad tests
Elsergany et al.
1998 [43]
33
Mean, 64
Range,
19–97
Up to 3 injections,
as needed
Open label,
single arm
Mean
follow-up,
18.8mos
Stamey Urinary
Incontinence
Scale; daily pad
usage; diaries
Cured: 48.5%
≥1 Stamey Scale grade
improvement: 33.3%
Improved from baseline, all
P<. 05
Herschorn et al.
1996 [44]
187
Mean, 62.9
Range,
15–94
Up to 3 injections Open label,
single arm
Mean
follow-up,
22mos
Direct patient
questioning
Cured: 23%
Improved: 52%
Homma et al.
1996 [45]
78 Mean,
57.1–63.5 Injections as needed Open label,
single arm 24mos
Patient-
administered
questionnaire
No SUI leaks: 6.7%
SUI episodes daily: 50%
<1 SUI episode/wk: 16.7%
<1 SUI episode/day: 26.7%
Mean injections, 1.9
Monga et al.
1995 [53]
60
Mean, 64
Range,
20–90
Up to 3 injections Open label,
single arm 24mos
Direct patient
questioning;
cystometry; stress
pad weight test
Patient-rated cured at 3, 12,
24mos: 46%, 40%, 48%;
improved: 40%, 37%, 20%
Objective measures
(cystometry/pad weight),
cured at 3, 12, 24 mos: 61%,
54%, 48%
Mean injections: 1.6
Richardson et al.
1995 [46]
42
Mean, 64
Range,
28–88
1–8 injections,
as needed
Open label,
single arm
Mean
follow-up,
46mos
LPP testing;
incontinence
grades (0–3)
Cured: 40%
Greatly improved/improved:
43%
Unchanged/worse: 17%
LPP improvement in women
cured/greatly improved:
65.4cmH2O
Mean injections: 2.4 in those
cured/greatly improved; 4.1 in
those improved/unchanged/
worse
Smith et al.
1997 [47]
94 67 Injections as needed Open label,
single arm
≥18mos Patient self-report
Initially dry/improved: 67%
Of these, 66.7% still
dry/improved at 18 mos; most
continent with 1–3 injections,
7 required 4 or more
Winters et al.
2000 [48]
58
Mean, 73.2
Range,
65–86
Injections as needed Open label,
single arm 24mos Telephone
interview
Maximal/moderate
improvement: 62.5%
Maximal/moderate QOL
improvement: 45.0%
Mean injections: 1.9
Mean time to SUI recurrence:
7.9 months8 Advances in Urology
Table 4: Continued.
Study N Age, y Treatment Study design Study
duration Eﬃcacy measures Eﬃcacy outcomes
Carbon-coated zirconium beads
Chrouser
et al. 2004
[51]
86 Mean, 67
Carbon-coated
zirconium beads
(n = 43)
GAX collagen
(n = 43)
Injections as needed
Post hoc, open
label versus
GAX collagen
(control)
36mos Patient
questionnaire
SUI improvement at 12, 24,
26mos:
Zirconium beads: 35%, 33%,
21%
GAX collagen: 33%, 19%, 9%
Overall, P = NS
Mean injections: N/A
Lightner
et al. 2001
[52]
235
Mean, 57.7
Mean, 57.0
Range,
26–84
Carbon-coated
zirconium beads
(n = 115)
GAX collagen
(n = 120)
Maximum 5
injections, as needed
Randomized,
controlled,
single blind
versus GAX
collagen
(control)
12mos
Stamey Urinary
Incontinence
Scale; stress pad
weight test
≥1 Stamey Scale grade
improvement:
Zirconium beads: 66.1%
GAX collagen: 65.8%
P = NS
Mean change in pad weight:
Zirconium beads: 27.9g
GAX collagen: 26.4
P = NS
Mean injections: 1.69 versus
1.55
Polydimethylsiloxane
Ghoniem
et al. 2009
[54]
247 Mean, 61
Polydimethylsiloxane
(n = 122)
GAX collagen
(n = 125)
Injections as needed
Randomized,
single blind
versus GAX
collagen
12mos
Stamey Urinary
Incontinence
Scale; stress pad
weight test;
I-QOL scores
≥1 Stamey Scale grade
improvement:
Polydimethylsiloxane: 61.5%
GAX collagen: 48.0%
I-QOL improvement:
Polydimethylsiloxane: 28.7%
GAX collagen: 26.4%
Pad weight test, P = NS
Koelbl et al.
1998 [55]
32
Mean, 64.3
Range,
39–85
Up to 2 injections Open label,
single arm 12mos
Stamey Urinary
Incontinence
Scale; cough stress
test; urethral
pressure
measurements
Cured: 60%
Increased maximal urethral
pressure, P = .03
Maher et al.
2005 [56]
45
Mean, 65
Range,
34–84
Mean, 63
Range,
43–81
Polydimethylsiloxane
(n = 23)
Pubovaginal sling
(n = 22)
Randomized,
controlled 60months Patient
questionnaire
Response rate, 60% in both
groups
Cured/improved:
Injection: 21%
Sling: 69%
Radley et al.
2001 [57]
56
Mean, 53
Range,
26–81
Up to 3 injections Open label,
single arm
Mean
follow-up,
19months
Patient
questionnaire
Cured/improved: 19.6%
Improved: 39.3%
No longer using pads: 19.6%
Tamanini
et al. 2003
[58]
21
Median,
47.4
Range,
33–54
Injections as needed
Open-label,
single arm,
interim results
12mos
Stamey Urinary
Incontinence
Scale; King’s
Health
Questionnaire;
pad usage; LPP
testing; stress pad
weight test
Cured: 76.2%
Improved: 66.7%
Mean decrease in daily pad
usage: 3.1
Mean pad weight decrease:
45.7 g
Tamanini
et al. 2006
[59]
21a
Median,
47.4
Range,
33–54
Injections as needed Open label,
single arm 60mos
Stamey Urinary
Incontinence
Scale; King’s
Health
Questionnaire;
pad usage; LPP
testing; stress pad
weight test
Cured: 40.0%
Improved: 33.3%
Mean decrease in daily pad
usage: 2.6
Mean pad weight decrease:
47.9 gAdvances in Urology 9
Table 4: Continued.
Study N Age, y Treatment Study design Study
duration Eﬃcacy measures Eﬃcacy outcomes
ter Meulen
et al. 2009
[60]
45
Mean, 55
Range,
40–76
Up to 2 injections, as
needed (n = 24)
At-home PFMT
(n = 21)
Randomized,
controlled,
open label
versus PFMT
(control)
12mos
I-QOL scores;
patient
questionnaire;
stress pad weight
test
Polydimethylsiloxane:
Cured: 88.9%
Improved: 82.4%
PFMT: 12-mo results N/A
Zullo et al.
2005 [61]
61
Mean, 69.7
Range,
55–82
One-time injection
Observational,
open-label,
single arm
60mos
VAS scores;
diaries, cough
stress test; PVR;
LPP
Cured: 18%
Improved: 39%
Cough stress test:
Cured patients: negative
Improved patients: positive
only when standing
Mean decrease in daily SUI
episodes: 3.8
Mean changes in PVR and
LPP: P = NS versus baseline
Calcium Hydroxylapatite
Mayer et al.
2007 [62]
296 Mean, 61 Up to 5 injections, as
needed
Randomized,
single blind
versus GAX
collagen
12mos
Stamey Urinary
Incontinence
Scale
≥1 Stamey Scale grade
improvement: 63.4% (calcium
Hydroxylapatite) versus 57.0%
(GAX collagen); P = .34
Abbreviations: LPP, leak point pressure; N/A, not available; NS, not signiﬁcant; PVR, postvoid residual; SUI, stress urinary incontinence; QOL, quality of life;
VAS, visual analogue scale.
aThese patients were already counted in Tamanini et al. 2003 [58], thus they were not included in the total patient numbers as given in the text.
available evidence was often found in open-label studies of
women with SUI, and search results of pelvic ﬂoor reha-
bilitation, pharmacotherapy, transurethral radiofrequency
collagen denaturation, and bulking agents were permitted
to include open-label studies that met the other eligibility
criteria.
A surprising ﬁnd of this literature review was the
paucity of prospectively designed studies of pelvic ﬂoor
rehabilitation of at least 12 months in duration, even though
PFMT has been used for treating patients with SUI since the
1950s [63, 64]. While some follow-up results were available
for up to 10 years or so following treatment initiation, the
original prospectively designed trials were no longer than
6 months in duration, leaving only 3 articles eligible for
inclusion in this paper.
Despite the paucity of prospective long-term trials,
noninvasive therapies continue to be widely used as ﬁrst-
line therapy [5, 9]. There are no or minimal associated
safety risks, the costs are low, and the short-term beneﬁts—
seen in approximately 60% to 77% of patients—are well
established [3, 8, 9, 65–67]. Lasting improvements, however,
are highly dependent on ongoing patient compliance. Pelvic
ﬂoor rehabilitation can yield beneﬁts that persist in some
patients for at least 12 months. However, for many patients
(up to 40% in one study [33]), PFMT failed within 1 year
of initiation, possibly indicating lack of adherence to these
therapies.
Similarly, large numbers of patients prescribed duloxe-
tine discontinued within the ﬁrst month, primarily because
of adverse events or lack of eﬃcacy.
Transurethral radiofrequency collagen denaturation and
urethral bulking agents oﬀer consistent beneﬁts that tended
to persist for at least 12 months for many patients. Results
with this procedure demonstrated that more than 50%
of patients continued to experience improvements in SUI
symptoms up to 3 years following a single treatment. This is
in contrast to results with urethral bulking agents, indicated
for treatment of patients with SUI due to ISD. With longer
follow-up, the beneﬁt seen with bulking agents diminished
and patients typically required additional injections. More-
over,thereportedpersistenceofresponsetoasingleinjection
was, in some cases, diﬃcult to distinguish from the eﬀect
of repeated injections. Additionally, the clinician should be
experienced in the technical aspects of the procedure to
optimize outcomes.
The primary goals of SUI treatment include safety,
eﬃcacy, and durability. In the present paper, pelvic ﬂoor
rehabilitation, with or without adjunctive therapy, was
shown to be an eﬀective and safe ﬁrst-line treatment for
the majority of female SUI patients, at least in the short-
term. Short-term data indicate that many women will
initially respond well to pelvic ﬂoor rehabilitation [65–67].
Moreover, for patients who persist with the technique over
time, improvements can be maintained for 1 year or longer,
but higher-quality, longer-term outcomes data with PFMT
are needed. Although no long-term advantage of adjunct
therapy with PFMT was described in the randomized,
controlled studies examined herein, an observational study
conducted over 60 months found that combination therapy
of PFMT with vaginal weights, electrical stimulation, and/or10 Advances in Urology
biofeedback was successful [68]. In patients with signiﬁ-
cant urethral sphincteric denervation injury and resultant
intrinsic deﬁciency, however, bulking agents or tight slings
may represent the only appropriate options besides a radical
diversion procedure.
While no long-term studies of weighted vaginal cones
werefound,short-termstudiesreporttreatmentsuccessrates
from 70% to 80% for up to 6 months [69, 70]. Additionally,
an observational trial by Komesu et al. found that the use
of pessaries was eﬀective in patients for up to 12 months
[71]. New products, such as the intravaginal polycarbonate
sphere(ColpexinSphere,AdamedInc.,Rutherford,NJ),may
also be useful in patients with SUI but require controlled
investigation. Eﬃcacydataavailabletodatearelimited touse
in women with pelvic organ prolapse [10].
Althoughthestudiesreviewedhereinrevealednoadverse
eﬀects associated with pelvic ﬂoor rehabilitation, treatment-
emergent adverse events have been reported with the use
of electrical stimulation and vaginal cones [72, 73]. Minor
bleeding and vaginitis have occurred with the use of vaginal
cones [72], while adverse events reported with electrical
stimulation included vaginal irritation, vaginal infection,
and occasional episodes of pain [72, 73]. No serious or
irreversible events were reported.
No pharmacologic treatment has been approved by
the US Food and Drug Administration for treatment of
SUI, but duloxetine is approved in many countries and is
sometimes prescribed by US physicians for SUI patients.
While hormone therapy is also sometimes prescribed oﬀ-
label as pharmacotherapy for women with SUI, three long-
term randomized controlled trials found that this therapy is
not consistently eﬀective. One 2-year trial of daily oral estriol
combinedwithPFMTversusPFMTalonefoundsigniﬁcantly
improved SUI scores in the estriol group (P<. 0001) for up
to 12 months [74]. However, a 2-year study of transdermal
ultra low-dose estradiol found no signiﬁcant diﬀerences
in the reduction of SUI symptoms versus placebo [75],
and a 4-year study of daily oral estrogen plus progestin
found that incontinence improved in only 20.9% of patients
and worsened in 38.8% of patients [76]. Importantly, oral
hormone therapy has been associated with cardiovascular
risks, in particular the risk of venous thromboembolism, in
postmenopausal women [77–79]. Although a recent study
indicated that transdermal hormone therapy may exhibit a
better safety proﬁle with regard to thrombotic risk [79], the
eﬀects are not fully established and the beneﬁts should be
weighed against the risks for individual patients [78, 79].
Among patients for whom nondrug and pharmacologic
conservative therapy fails, surgical intervention is usually
recommended. As an alternative to surgery, female patients
with SUI may consider nonsurgical procedures, including
urethral bulking agent injections or transurethral radiofre-
quency collagen denaturation, depending on whether they
are diagnosed with SUI associated with ISD or with
SUI associated with urethral hypermobility. Because of
these distinctions, careful pretreatment patient evaluation
is necessary; selecting the proper type of technique for a
given patient may help to optimize outcomes with such
procedures.
Withradiofrequencycollagendenaturation,thereviewed
studies indicate that a single treatment procedure is associ-
ated with lasting SUI improvements, in one trial persisting
in 56% of patients for up to 3 years [40]. This compares
positively with results of multiple injections with bulking
agents for patients with SUI and with some of the more
recentsurgicalresults.OneanalysisindicatedimprovedQOL
at 1 year posttreatment [38]. Safety was described as good,
with the most common adverse events including dysuria and
urinary tract infection; no serious complications with this
procedure have been reported.
It is important to distinguish this procedure from an
olderradiofrequencyprocedure,transvaginalradiofrequency
tissueablation(SURx;CooperSurgical,Trumbull,CT).With
transvaginal tissue ablation, an incision was made through
the vagina, lateral to the urethra, and the vaginal mucosa
was dissected oﬀ the underlying endopelvic fascia to expose
the surface area for treatment. Radiofrequency energy was
applied at high temperatures (85◦C) to large areas of tissue,
causing blanching and gross shrinkage secondary to scarring
and coagulation necrosis of the aﬀected tissue [80, 81].
Tissue damage likely resulted in nerve ending damage and
the development of worsening urethral sphincteric function
due to partial denervation. The procedure was typically
performed in a hospital setting under general anesthesia, but
is no longer marketed following reports of low cure rates and
the frequent need for additional corrective treatment [82–
84].
In distinct contrast, transurethral collagen denaturation
requires no incision, and radiofrequency energy at low
temperatures of 65◦C is applied to very small areas of
submucosal tissue at much lower temperatures, resulting
in tissue remodeling rather than gross tissue shrinkage or
necrosis.
The present review of the literature indicates that long-
term outcomes vary among available bulking agents. GAX
collagen appears to oﬀer less durable improvements, more
often requiring repeat injections, compared with the newer
silicone or polymer-based agents, which are considered more
permanent. In the longest follow-up studies of such urethral
bulking agents [59, 61], cure rates ranged from 18% to 45%
and improvement rates ranged between 33% and 39% at
50 to 60 months posttreatment. Safety with these products
appearstobegenerallygood,althoughseriouscomplications
rarely occur, such as migration of the bulking material into
other tissues and urethral erosion [85, 86]. The literature
search revealed one long-term study of the injectable agent
ethylene vinyl alcohol (Tegress; Bard, Covington, GA; N =
33) [87], but this agent was found to have signiﬁcant
adverse eﬀects, such as tissue necrosis, and is no longer
marketed. It appears that the ideal bulking agent has not yet
been identiﬁed. Such an agent would be inert, long-lasting,
nonmigrating, adjustable, and easy to inject.
4.1.Limitations. Thepresentpaperhassomelimitationsthat
must be considered. One diﬃculty found in this literature
review is the lack of standardized methodology as well as
varyingterminology usedinSUIstudies,making itproblem-
atic to directly compare results. Among the studies included,Advances in Urology 11
thereisavariabilityindesign,baselinepatientcharacteristics,
speciﬁcally with regard to the type of incontinence, the
method of diagnosing SUI, and the severity of symptoms.
This could account for the variability in outcomes and the
range in success rates between diﬀerent studies of similar
therapies. Such disparities have been reported before [88–
90], suggesting an important need to apply standardized
terminology and methods to all studies of SUI.
The PFMT regimens employed also varied widely,
making cross-study comparisons of outcomes diﬃcult to
interpret. Moreover, across all types of therapies reviewed
currently, SUI eﬃcacy end points diﬀered substantially.
Finally, no head-to-head comparisons of diﬀerent classes
of nonsurgical techniques were reviewed in this study
(e.g., PFMT versus a bulking agent; a bulking agent ver-
sus radiofrequency collagen denaturation). Head-to-head
randomized controlled studies of nonsurgical therapies for
patients with SUI are diﬃcult to design primarily because
each treatment is approved for use in diﬀerent patient pop-
ulations, making comparison of results between treatment
groups diﬃcult.
A common problem that exists among long-term SUI
studies is the patient dropout rate. While it is known that
some patients go on to have surgery, others may decide they
no longer have time or desire to participate in follow-up
visits over several years. As a result, the patient population
in long-term SUI studies may diminish over time, making it
diﬃcult to compare results. Another common discrepancy
that occurs when comparing study results for any SUI
treatment was highlighted in a recent clinical study. A 24-
month study by Albo et al. [91]f o u n dm u c hl o w e rc u r er a t e s
for the Burch colposuspension (47%) and fascial sling (38%)
procedures than those commonly reported in the literature
(up to 90%). The diﬀerences in success rates were most likely
attributable to the stricter deﬁnition of cured used in the
studycomparedwithvaryingdeﬁnitionsofcuredordryused
in previous studies. Such variability in outcomes deﬁnitions
exists in studies of all SUI treatments, not just surgeries, and
can make it diﬃcult to compare results between studies [88–
90, 92, 93].
5. Conclusions
While pelvic ﬂoor rehabilitation is generally the ﬁrst-line
treatment for female patients with SUI, the long-term
beneﬁts are unclear and further clinical studies of at least
12 months in duration are needed. This literature analysis
suggests that minimally invasive, nonsurgical transurethral
radiofrequency collagen denaturation is an eﬀective option
forpatientswithSUIduetourethralhypermobilitywhohave
failed pelvic ﬂoor rehabilitation and who cannot or choose
not to undergo surgery. Evidence suggests generally good
safety and beneﬁts that persist for at least 3 years for the
majority of patients who undergo this procedure. Bulking
agents used for patients with SUI due to ISD have also
demonstrated eﬀectiveness at 1 year, but results, particularly
with older agents, tend to diminish upon further follow-up;
however, improvement may be enhanced through repeated
injections. Each of these minimally invasive options appears
to present an intermediate management step after failure of
conservative therapy but prior to surgery.
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